Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. is asking shareholders to approve multiple capital-structure actions at a Special Meeting on April 20, 2026
The proposals seek (i) to increase authorized voting Common Stock from 298,000,000 to 500,000,000 (total authorized shares from 352,475,074 to 554,475,074); (ii) and (iii) to authorize two discretionary reverse stock splits, each at a ratio between 1-for-15 and 1-for-150; and (iv) to approve, for Nasdaq Rule 5635(d) purposes, the issuance of shares on exchange of a secured promissory note issued to Streeterville Capital with original principal $10,810,000 (outstanding approximately $7,057,500 as of March 12, 2026), which could result in issuance of ~13,232,241 Exchange Shares (about 106.55% of the 12,419,277 shares outstanding as of the Record Date).
The company disclosed Nasdaq non-compliance for a sub-$1 bid price and has appealed; approvals are requested under both the Votes Cast Standard and the Majority of Outstanding Standard to preserve board flexibility. Shareholder votes will also permit adjournments to solicit additional proxies.
Jaguar Health director John Micek received equity awards as board compensation. On December 11, 2025 he was granted stock options for 7,377 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035, under the 2014 Stock Incentive Plan. The options vest monthly over 12 months while he continues serving on the boards of Jaguar Health and its subsidiary Napo Therapeutics.
On the same date he also received 7,377 restricted stock units, each representing one share of common stock, which vest on December 11, 2026. After the grant he directly holds 7,430 common shares, and the vested RSU shares will be delivered on the vesting date specified in the grant notice.
Jaguar Health, Inc. reworked several financing arrangements with Uptown Capital and Streeterville Capital. The company postponed monthly royalty payments under two $12 million royalty interests from April 1, 2026 to July 1, 2026 and reduced each related Royalty Repayment Amount by ten percent, to $11,125,282.54 and $12,428,782.20. Jaguar and subsidiary Napo Pharmaceuticals also amended secured notes with Streeterville: the 2021 Note’s maturity was extended to July 1, 2026 and its Outstanding Balance cut ten percent to $6,596,304.11, while the 2025 Note’s maturity was extended to March 12, 2029 with an Outstanding Balance of $7,048,021.86. Napo granted Streeterville a security interest in specified Lechlemer and TDPRV collateral to secure the 2025 Note. In a separate warrant termination agreement, investors agreed to terminate warrants exercisable for 48,211 shares of Jaguar’s common stock.
Jaguar Health, Inc. reported that Nasdaq notified the company on March 5, 2026 that it is no longer in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of its common stock has closed below $1.00 per share for the previous 30 consecutive business days.
Nasdaq also stated the company is not eligible for a standard compliance period because it effected one or more reverse stock splits over the prior two years with a cumulative ratio of at least 250-to-1. Unless Jaguar Health requests an appeal before a Nasdaq Hearings Panel by March 12, 2026, its securities would be scheduled for delisting.
Jaguar Health intends to timely request this appeal, which would automatically stay any further suspension or delisting action at least until the hearing process is concluded. The company cautions there can be no assurance that the Panel will grant continued listing or that it will regain and maintain compliance with Nasdaq’s standards.
Jaguar Health, Inc. detailed the terms of a special one-time dividend of its new Series O Convertible Preferred Stock, giving one-tenth of a Series O share for each common share and for common shares issuable under Eligible Warrants outstanding as of the March 2, 2026 record date. The company designated 1,557,000 shares of preferred stock as Series O, which carry no regular dividends and almost no voting rights. Each Series O share has a stated value of $8.01 and will convert into common stock based on a market-based conversion price, subject to a 19.99% beneficial ownership cap per holder. Jaguar may choose to convert all outstanding Series O before December 31, 2026, or they will automatically convert on that date, with any excess above the cap potentially delivered as pre-funded warrants exercisable at $0.001 per share.
Jaguar Health declared a special one-time stock dividend of Series O Convertible Preferred Stock, granting one-tenth of one Series O share for each share of common stock and for Eligible Warrants covering 2,400,765 common shares held on the March 2, 2026 record date. The dividend is expected to be paid on March 4, 2026. The Series O Preferred Stock is non-transferable, pays no dividends, has minimal liquidation preference, and carries almost no voting rights, but will convert into common stock at the company’s election or automatically on December 31, 2026 based on a market-linked conversion price, subject to a 19.99% beneficial ownership cap per holder. Jaguar’s risk disclosures highlight that full conversion of the Series O Preferred Stock and potential future exchanges of approximately $30 million of debt into common stock could result in substantial dilution and pressure on the share price. The company also warns of ongoing risks to maintaining its Nasdaq listing following multiple reverse stock splits and evolving listing standards.
Lincoln Alternative Strategies LLC has filed an amended Schedule 13G reporting that it no longer beneficially owns any common stock of Jaguar Health, Inc. The firm now reports ownership of 0 shares, representing 0% of the outstanding common stock as of the event date January 12, 2026.
The filing states Lincoln Alternative Strategies has no sole or shared voting or dispositive power over Jaguar Health shares and confirms its holdings are below the 5% reporting threshold. It also certifies that any securities previously held were not acquired or held for the purpose of influencing control of Jaguar Health.
Jaguar Health entered a series of privately negotiated exchange agreements with Iliad Research and Trading and Streeterville Capital, converting royalty and preferred stock obligations into pre-funded common stock warrants. The company issued pre-funded warrants to Iliad to purchase 1,553,844 shares in exchange for a $1,187,914.07 reduction of an October 2020 royalty interest and 1,111,837 shares to Streeterville for an $850,000 reduction of an August 2022 royalty interest. Jaguar also exchanged and cancelled Series L and Series M preferred stock held by both investors, issuing additional pre-funded warrants for 719,424, 3,249,908, 2,870,503 and 2,270,765 shares of common stock. All pre-funded warrants are immediately exercisable at $0.001 per share and include a 9.99% beneficial ownership cap, and were issued as unregistered securities relying on the Section 3(a)(9) exemption.
Jaguar Health, Inc. reported an equity compensation award to executive Steven R. King, who serves as Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary. On December 11, 2025, he was granted 11,740 shares of common stock, bringing his directly held common stock to 11,885 shares. These shares reflect restricted stock units granted under the company’s 2014 Stock Incentive Plan and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date.
On the same date, King also received a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests in equal monthly installments over 12 months from the grant date, contingent on his continued employment. Both the restricted stock units and options were approved by the board of directors as part of the company’s stock incentive program, and were reported as directly owned.
Jaguar Health, Inc. reported an equity compensation grant to Chief Executive Officer and President Lisa A. Conte, who is also a director. On December 11, 2025, she received 28,592 restricted stock units of common stock at a price of $0, increasing her directly owned common shares to 29,258. Each unit represents one share and will vest on December 11, 2026, with shares delivered on that date.
On the same date, she was granted stock options for 28,592 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. These options vest ratably on a monthly basis over 12 months from the grant date, contingent on her continued employment, and were issued under the company’s 2014 Stock Incentive Plan.